Efficacy of Lenvervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection

0 538

Cited 0 times in

Authors: Hye Won Lee ; Jun Yong Park ; Taegon Hong ; Min Soo Park ; Sang Hoon Ahn

Citation: CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, Vol.18(13) : 3043-3045.e1, 2020-12

Abstract: The mechanism of action of hepatitis B immunoglobulin (HBIG) for chronic hepatitis B (CHB) treatment is not fully understood. A clinical trial in Japan suggested that HBIG therapy might benefit patients with CHB.1 Lenvervimab, a recombinant monoclonal HBIG developed by GC Pharma (Yongin, South Korea), has been screened from an anti-HBs-enriched phage-display library cloned from hepatitis B vaccine-boosted human blood cells and was produced in Chinese hamster ovary cells.2-4.

Full Text: https://www.sciencedirect.com/science/article/pii/S1542356519310894

Appears in Collections:: 6. Others (기타) > Dept. of Clinical Pharmacology (임상시험센터) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

Yonsei Authors: Park, Jun Yong(박준용) https://orcid.org/0000-0001-6324-2224
Ahn, Sang Hoon(안상훈) https://orcid.org/0000-0002-3629-4624
Lee, Hye Won(이혜원) https://orcid.org/0000-0002-3552-3560
Hong, Tae Gon(홍태곤) https://orcid.org/0000-0001-7490-0085

Show full item record Find it @ YMLIB

YUHSpace: Efficacy of Lenvervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection